72873-74-6

72873-74-6 structure

Name: SKF 86002
Chemical Name: 6-(4-fluorophenyl)-5-pyridin-4-yl-2,3-dihydroimidazo[2,1-b][1,3]thiazole
CAS Number: 72873-74-6
Molecular Formula: C₁₆H₁₂FN₃S
Molecular Weight: 297.350
Catalog: Signaling Pathways MAPK/ERK Pathway p38 MAPK
Create Date: 2018-12-01 12:23:30
Modify Date: 2024-01-03 22:56:43
SKF-86002 is a potent inhibitor of p38 MAP kinase wit IC50 of 0.5-1 uM; inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50 = 1 μM).IC50 value:Target: p38 MAPK inhibitorin vitro: SKF-86002 inhibited prostaglandin H2 (PGH2) synthase activity (IC50 120 microM) as well as prostanoid production by rat basophilic leukemia (RBL-1) cells (IC50 70 microM) and its sonicate (IC50 100 microM) and human monocytes (IC50 1 microM). In addition, SK&F 86002 inhibited the generation of dihydroxyeicosatetraenoic acid (diHETE) and 5-hydroxyeicosatetraenoic acid (5-HETE) by a high speed supernatant fraction of RBL-1 cells (IC50 10 microM) [1]. differentiation of HL-60 cells toward the neutrophil phenotype resulted in a loss in c-Jun NH2-terminal kinase activation with concomitant acquisition of formylmethionylleucylphenylalanine-stimulatable and stress-inducible p38 MAPK activity as well as apoptosis blockade by SKF-86002 [2]. SKF-86002 blocked superoxide anion production in response to FMLP and reduced adhesion and chemotaxis in response to PAF or FMLP [3].

Name	6-(4-fluorophenyl)-5-pyridin-4-yl-2,3-dihydroimidazo[2,1-b][1,3]thiazole
Synonyms	5-(4-pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)-thiazole MFCD00869367 6-(4-Fluorophenyl)-5-(4-pyridinyl)-2,3-dihydroimidazo[2,1-b][1,3]thiazole 6-(4-Fluorophenyl)-5-(pyridin-4-yl)-2,3-dihydroimidazo[2,1-b][1,3]thiazole Imidazo[2,1-b]thiazole, 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)- SKF-86002

Description	SKF-86002 is a potent inhibitor of p38 MAP kinase wit IC50 of 0.5-1 uM; inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50 = 1 μM).IC50 value:Target: p38 MAPK inhibitorin vitro: SKF-86002 inhibited prostaglandin H2 (PGH2) synthase activity (IC50 120 microM) as well as prostanoid production by rat basophilic leukemia (RBL-1) cells (IC50 70 microM) and its sonicate (IC50 100 microM) and human monocytes (IC50 1 microM). In addition, SK&F 86002 inhibited the generation of dihydroxyeicosatetraenoic acid (diHETE) and 5-hydroxyeicosatetraenoic acid (5-HETE) by a high speed supernatant fraction of RBL-1 cells (IC50 10 microM) [1]. differentiation of HL-60 cells toward the neutrophil phenotype resulted in a loss in c-Jun NH2-terminal kinase activation with concomitant acquisition of formylmethionylleucylphenylalanine-stimulatable and stress-inducible p38 MAPK activity as well as apoptosis blockade by SKF-86002 [2]. SKF-86002 blocked superoxide anion production in response to FMLP and reduced adhesion and chemotaxis in response to PAF or FMLP [3].
Related Catalog	Signaling Pathways >> MAPK/ERK Pathway >> p38 MAPK Research Areas >> Inflammation/Immunology
References	[1]. Griswold DE, et al. SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Biochem Pharmacol. 1987 Oct 15;36(20):3463-70. [2]. Frasch SC, et al. p38 mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils. J Biol Chem. 1998 Apr 3;273(14):8389-97. [3]. Nick JA, et al. Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP. J Clin Invest. 1997 Mar 1;99(5):975-86.

Density	1.4±0.1 g/cm3
Boiling Point	476.1±55.0 °C at 760 mmHg
Melting Point	189-190ºC(lit.)
Molecular Formula	C₁₆H₁₂FN₃S
Molecular Weight	297.350
Flash Point	241.7±31.5 °C
Exact Mass	297.073608
PSA	56.01000
LogP	1.90
Vapour Pressure	0.0±1.2 mmHg at 25°C
Index of Refraction	1.713
Storage condition	2-8℃

Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xi: Irritant;
Risk Phrases	36/37/38
Safety Phrases	26-36
RIDADR	NONH for all modes of transport
HS Code	2934100090

106465-75-2

~92%

72873-74-6

Literature: Lantos, Ivan; Gombatz, Kerry; McGuire, Michael; Pridgen, Lendon; Remich, James; Shilcrat, Susan Journal of Organic Chemistry, 1988 , vol. 53, # 18 p. 4223 - 4227

87532-41-0

72873-74-6

Literature: Lantos, I.; Bender, P. E.; Razgaitis, K. A.; Sutton, B. M.; DiMartino, M. J.; et al. Journal of Medicinal Chemistry, 1984 , vol. 27, # 1 p. 72 - 75

110-86-1

72873-74-6

Literature: Lantos, Ivan; Gombatz, Kerry; McGuire, Michael; Pridgen, Lendon; Remich, James; Shilcrat, Susan Journal of Organic Chemistry, 1988 , vol. 53, # 18 p. 4223 - 4227

72882-75-8

106-93-4

72873-74-6

72873-75-7

Literature: Lantos, I.; Bender, P. E.; Razgaitis, K. A.; Sutton, B. M.; DiMartino, M. J.; et al. Journal of Medicinal Chemistry, 1984 , vol. 27, # 1 p. 72 - 75

Precursor 5
106465-75-2 87532-41-0 110-86-1 72882-75-8
106-93-4
DownStream 1
72873-77-9

HS Code	2934100090
Summary	2934100090 other compounds containing an unfused thiazole ring (whether or not hydrogenated) in the structure VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0%

72873-74-6	116339-68-5
133485-77-5	300561-58-4
130495-35-1	121034-72-8
40737-56-2	79599-96-5
55272-99-6	124796-27-6